What is Inbrain Neuroelectronics?
Inbrain Neuroelectronics is at the forefront of developing advanced neuroelectronic therapies powered by sophisticated machine learning algorithms. The company's innovative graphene-brain interfaces are engineered to achieve unprecedented resolution in neural signal reading. These interfaces are designed to detect therapy-specific biomarkers and enable highly focal adaptive neuromodulation, thereby enhancing outcomes in personalized neurological treatments. The company's focus on precision and personalization in neurological therapies positions it as a key player in the rapidly evolving medtech landscape.
How much funding has Inbrain Neuroelectronics raised?
Inbrain Neuroelectronics has raised a total of $66.8M across 2 funding rounds:
Other Financing Round
$16.9M
Series B
$50M
Other Financing Round (2021): $16.9M with participation from Alta Life Sciences and Asabys Partners
Series B (2024): $50M led by Asabys Partners, Avançsa, Aliath Bioventures, Vsquared, and EIC IMPACT TRUST - EIC IMPACT FUND - Eastern Investment Centers
Key Investors in Inbrain Neuroelectronics
Alta Life Sciences
Alta Life Sciences, part of AltamarCAM Partners, is a significant backer specializing in global alternative investments, with a particular focus on life sciences. They are committed to delivering strong performance and ESG principles in their venture capital activities.
Asabys Partners
Asabys Partners is a Barcelona-based investment firm dedicated to advancing breakthrough innovations in healthcare and life sciences, aiming to improve patient lives through disruptive technologies and providing hands-on support to its portfolio companies.
Vsquared
Vsquared Ventures is a venture capital firm that invests in cutting-edge technologies with the potential to advance society, including those in the deep tech and space exploration sectors, supporting entrepreneurs in high-risk, high-reward ventures.
What's next for Inbrain Neuroelectronics?
With the recent major strategic investment, Inbrain Neuroelectronics is poised to accelerate its research and development initiatives, further refine its proprietary graphene-brain interface technology, and expand its clinical trial programs. This backing is expected to fuel the company's growth trajectory, enabling it to scale its operations and bring its transformative neurological therapies to a wider patient population. The strategic nature of this financing suggests a focus on market penetration and the establishment of key partnerships within the healthcare ecosystem, underscoring the company's ambition to lead in the field of personalized neurological care.
See full Inbrain Neuroelectronics company page
